Figure 1.

(a) Serum M2BPGi levels in the overall study population and according to the etiology of acute liver injury. Differences were evaluated by the Kruskal-Wallis test, and significant differences were verified by Dunn’s multiple comparison test. *p<0.05. (b) The serum M2BPGi levels at the times of the diagnosis and at the normalization of ALT in 26 patients. The serum M2BPGi level was 2.2 (range, 0.38-9.7) COI at the time of the diagnosis and 0.68 (range, 0.15-1.87) COI at the time of serum ALT normalization (p<0.0001). Differences between the two groups were evaluated by Wilcoxon’s signed-rank test. (c) The correlation between the serum M2BPGi level and the time to serum ALT normalization in 46 patients. The serum M2BPGi level (r=0.53, p<0.0001) was positively correlated with the time to serum ALT normalization. Correlations were evaluated by calculating Spearman’s rank-correlation coefficient (r). AI: autoimmune liver disease, IM: infectious mononucleosis, DILI: drug-induced liver injury, HBV: hepatitis B virus, HAV: hepatitis A virus, EU: etiology unknown, ALT: alanine aminotransferase, M2BPGi: Mac-2-binding protein glycosylation isomer